Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patrick Griffith

Internal Medicine Jennings, LA Medical Doctor

NPI 1194828301 CMS profile 53825

1902 Johnson St, Jennings, LA 70546

Open in the dashboard

General payments

$3,292

190 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patrick Griffith of Jennings, LA is reported in the CMS Open Payments database as having received $3,292 across 190 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $191 10
2024 General $423 27
2023 General $654 32
2022 General $835 48
2021 General $712 42
2020 General $176 9
2019 General $302 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Griffith
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Patrick Griffith were reported at $191. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Patrick Griffith Internal Medicine median Middle half National median
2019 $302 $159 $48–$570 $163
2020 $176 $119 $33–$402 $114
2021 $712 $135 $37–$521 $132
2022 $835 $141 $42–$496 $149
2023 $654 $149 $45–$519 $160
2024 $423 $154 $47–$537 $164
2025 $191 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $861 62 payments
  2. Pfizer Inc. $559 36 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $400 21 payments
  4. Novo Nordisk Inc $288 15 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $231 2 payments
  6. Lilly USA, LLC $227 14 payments
  7. Novartis Pharmaceuticals Corporation $168 10 payments
  8. Astellas Pharma US Inc $100 1 payment
  9. Kowa Pharmaceuticals America, Inc. $61 3 payments
  10. Esperion Therapeutics, Inc. $59 4 payments
  11. Other $340 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,181 188 payments
  2. Education $112 2 payments
Products named General payments · program years 2019–2025
  1. TRINTELLIX $400 21 payments
  2. UBRELVY $367 25 payments
  3. COLOGUARD $322 25 payments
  4. QULIPTA $304 21 payments
  5. RYBELSUS $288 15 payments
  6. JARDIANCE $231 2 payments
  7. VRAYLAR $226 14 payments
  8. Ozempic $184 14 payments
  9. SYNTHROID $157 12 payments
  10. EUCRISA $143 2 payments
  11. Other $1,409 107 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 229 drugs

Part D claims

24,115

Median for Internal Medicine: 777

Drug cost

$1,171,797

Median for Internal Medicine: $73,373

Branded share of claims

19.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 175 $189,192
Ozempic Semaglutide Brand 143 $141,868
Eliquis Apixaban Brand 151 $86,617
Xarelto Rivaroxaban Brand 92 $63,861
Trulicity Dulaglutide Brand 64 $61,754
Myrbetriq Mirabegron Brand 71 $40,786
Tradjenta Linagliptin Brand 39 $37,017
Rybelsus Semaglutide Brand 29 $35,987
Jardiance Empagliflozin Brand 30 $34,581
Linzess Linaclotide Brand 37 $24,192

The 10 drugs with the highest cost, of 229 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 78 billing codes

Paid by Medicare

$240,841

Of which drugs: $1,160

Medicare patients

853

Average age 75

Services billed

20,832

487 women, 366 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Depression 48%
Ischemic heart disease 42%
Heart failure 39%
Diabetes 36%
Chronic kidney disease 34%
Atrial fibrillation 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 76 120 $490
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 90 478 $302
Injection, testosterone cypionate, 1 mg J1071 Office 15 16,044 $178
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 44 205 $168
Injection, ceftriaxone sodium, per 250 mg J0696 Office 14 31 $10

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $125
$125 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $89
$89 32 —
SYNTHROID
  • AbbVie, Inc. $72
$72 178 —
QULIPTA
  • AbbVie, Inc. $55
$55 — —
NEXLETOL
  • Esperion Therapeutics, Inc. $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

190 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record